Cell & Gene Unscripted: Honest conversations with the experts shaping what's next
Cell and gene therapy isn't advanced by easy answers. It's advanced by difficult choices, evolving science, and the people willing to challenge assumptions. This series explores what those decisions mean and what's at stake.
Hosted by Parexel's Head of Cell & Gene Therapy and Early Phase, Chris Learn, Ph.D. M.B.A., P.M.P., this exclusive video series brings together industry leaders to unpack the trade-offs, tensions, and opportunities shaping the future of the field, from regulatory strategy and trial execution to patient access and real-world evidence.
No rehearsed talking points. No surface-level perspectives. Just honest discussions designed to help biotech and biopharma leaders navigate an increasingly complex landscape.
Related Insights
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Adapting at the pace of development: Why operating model flexibility is key to success
Oct 21, 2026
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
The next generation of FSP will be defined by results, not headcount
Oct 8, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Sep 22, 2026
Blog
Cell & Gene Unscripted: Real-world evidence
Sep 16, 2026
Related Insights
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Adapting at the pace of development: Why operating model flexibility is key to success
Oct 21, 2026
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
The next generation of FSP will be defined by results, not headcount
Oct 8, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
Webinar
The evidence gap in hematology: From trial endpoints to patient outcomes
Oct 1, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Blog
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Sep 22, 2026
Blog
Cell & Gene Unscripted: Real-world evidence
Sep 16, 2026